Searched for
EXELAN PHARMACEUTICALS
Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possi...- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible b...
- ET Businesswoman of the Year 2021: Samina Hamied - The woman who carries forward a storied legacy, seeking profit, but never at the cost of values“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...
- FDA norms punch a Rs 5,000 crore hole in Pharma IndustryIn FY16, the top five — Sun Pharma, Dr Reddy’s, Lupin, Aurobindo and Cipla — ran up a total bill of Rs 3,497 crore in legal and professiona...
- Cipla seals Invagen and Exelan deals in USThe deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 m...
- PuraCap suit may impact Cipla's $550-million dealIn an email response seeking comment, PuraCap said its complaint was publicly available at the US District Court for the Southern District ...
- Sensex rangebound; Nifty holds 8,100; Bharat Forge slumps 5%, SCI gains 7%The S&P BSE Sensex recouped losses after falling as much as 133 points in opening trade on Wednesday following muted trend seen in other As...
- Twelve stocks in focus in Wednesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- Goal to make US contribute 20% to our business by 2020: Sudhanshu Priyadarshi, CiplaWe have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.
- Cipla's ratings unlikely to be impacted by US acquisitions: India RatingsIndia Ratings & Research today said Cipla's ratings are unlikely to be affected by the recent cash-rich acquisitions of two US-based compan...
- Post Invagen sale, Hetero says to strengthen US operationsCipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.
- Cipla surges on US acquisitions worth $550 millionCipla shares climbed over 3% in morning trade after the company said its UK-based subsidiary, Cipla EU, will acquire two US-based companies.
Load More
